Skip to main content
. 2017 Nov 20;8(64):107612–107620. doi: 10.18632/oncotarget.22544

Table 1. Clinical and laboratory characteristics of the participants.

Variables Metastasis (n = 58) Non-metastasis (n = 32) P-value
Breast cancer (n) 9 3 NA
Lung cancer (n) 9 4 NA
Colon cancer (n) 6 2 NA
Gastric cancer (n) 7 3 NA
Rectal cancer (n) 5 3 NA
Lymphoma (n) 3 6 NA
Ovarian cancer (n) 5 2 NA
Cervical cancer (n) 3 2 NA
Esophagus cancer (n) 3 2 NA
Nasopharynx cancer (n) 3 2 NA
Other cancers (n) 5 3 NA
Ages (years) 51.5 (12.2) 47.4 (15.5) 0.102
Gender (males,%) 25 (43.9) 12 (44.4) 0.056
DcR3 (pg/ml)* 335.6 (413.6) 228.5 (173.7) <0.05
PDW (%) 14.1 (13.9) 11.8 (1.9) 0.058
Haemoglobin (g/dl)* 112.2 (24.1) 124.5 (16.7) <0.05
Hematocrit (%)* 34.6 (6.8) 38.1 (5.1) <0.05
DcR3 × PDW ÷ (HGB × HCT)*** 1.4 (1.9) 0.4 (0.2) <0.001

Data are presented as means(SD). P-Value was calculated by chi-square test (Age) or Mann-Whitney U test. Metastasis includes lymph node metastasis and distant metastasis. The number of patients tested (n) is shown.

*compared with non-metastatic cancers, P < 0.05.

***compared with non-metastatic cancers, P < 0.001.